These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 22264968)

  • 1. The cost-effectiveness of different chemotherapy strategies for patients with poor prognosis advanced colorectal cancer (MRC FOCUS).
    Manca A; Asseburg C; Bravo Vergel Y; Seymour MT; Meade A; Stephens R; Parmar M; Sculpher MJ
    Value Health; 2012 Jan; 15(1):22-31. PubMed ID: 22264968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
    Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
    Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence.
    Wade R; Duarte A; Simmonds M; Rodriguez-Lopez R; Duffy S; Woolacott N; Spackman E
    Pharmacoeconomics; 2015 May; 33(5):457-66. PubMed ID: 25616671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Treatment Sequences of Chemotherapies and Targeted Biologics for Elderly Metastatic Colorectal Cancer Patients.
    Parikh RC; Du XL; Robert MO; Lairson DR
    J Manag Care Spec Pharm; 2017 Jan; 23(1):64-73. PubMed ID: 28025930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients.
    Mullins CD; Hsiao FY; Onukwugha E; Pandya NB; Hanna N
    Cancer; 2012 Jun; 118(12):3173-81. PubMed ID: 22020739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.
    Seymour MT; Maughan TS; Ledermann JA; Topham C; James R; Gwyther SJ; Smith DB; Shepherd S; Maraveyas A; Ferry DR; Meade AM; Thompson L; Griffiths GO; Parmar MK; Stephens RJ; ;
    Lancet; 2007 Jul; 370(9582):143-152. PubMed ID: 17630037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis.
    Goldstein DA; Chen Q; Ayer T; Howard DH; Lipscomb J; El-Rayes BF; Flowers CR
    J Clin Oncol; 2015 Apr; 33(10):1112-8. PubMed ID: 25691669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of Capecitabine + Irinotecan Versus Leucovorin + Fluorouracil + Irinotecan in the Second-line Treatment of Metastatic Colorectal Cancer in China.
    Wu Q; Zhang P; Wang X; Zhang M; Liao W; Li Q
    Clin Ther; 2020 Nov; 42(11):2148-2158.e2. PubMed ID: 32981743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan.
    Kashiwa M; Matsushita R
    Clin Ther; 2020 Jul; 42(7):1361-1375. PubMed ID: 32616433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
    Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P
    Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-minimization analysis of sequence changes between FOLFIRI and FOLFOX6 therapy for advanced colorectal cancer in Japan.
    Miyazaki Y; Harada T; Akase T; Arakawa I; Inoue T
    Clin Ther; 2009; 31 Pt 2():2433-41. PubMed ID: 20110051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer.
    Levy-Piedbois C; Durand-Zaleski I; Juhel H; Schmitt C; Bellanger A; Piedbois P
    Ann Oncol; 2000 Feb; 11(2):157-61. PubMed ID: 10761749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of treatments for metastatic pancreatic cancer based on PRODIGE and MPACT trials.
    Zhou J; Zhao R; Wen F; Zhang P; Wu Y; Tang R; Chen H; Zhang J; Li Q
    Tumori; 2016 Jun; 2016(3):294-300. PubMed ID: 27056335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.
    Hoyle M; Crathorne L; Peters J; Jones-Hughes T; Cooper C; Napier M; Tappenden P; Hyde C
    Health Technol Assess; 2013 Apr; 17(14):1-237. PubMed ID: 23547747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer.
    Hoyle M; Peters J; Crathorne L; Jones-Hughes T; Cooper C; Napier M; Hyde C
    Value Health; 2013; 16(2):288-96. PubMed ID: 23538180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer.
    Riesco-Martínez MC; Berry SR; Ko YJ; Mittmann N; Giotis A; Lien K; Wong WW; Chan KK
    J Oncol Pract; 2016 Jun; 12(6):e710-23. PubMed ID: 27143148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU.
    Iveson TJ; Hickish T; Schmitt C; Van Cutsem E
    Eur J Cancer; 1999 Dec; 35(13):1796-804. PubMed ID: 10673994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma.
    Hillner BE; Schrag D; Sargent DJ; Fuchs CS; Goldberg RM
    Cancer; 2005 Nov; 104(9):1871-84. PubMed ID: 16177989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
    Tappenden P; Jones R; Paisley S; Carroll C
    Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-utility analysis of the newly recommended adjuvant chemotherapy for resectable gastric cancer patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Gastric Cancer.
    Chongqing T; Liubao P; Xiaohui Z; Jianhe L; Xiaomin W; Gannong C; Siying W; Lihui O; Ziying Z
    Pharmacoeconomics; 2014 Mar; 32(3):235-43. PubMed ID: 23709451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.